Takeaways: Health Canada’s approval of Dawnzera (donidalorsen) gives CELYSTRA a first‑in‑class, RNA‑targeted prophylaxis for hereditary angioedema (HAE) in patients ≥12 years, with Q4W/Q8W...
Browsing Tag: RNA-targeted therapy
Takeaways: Health Canada’s approval of Dawnzera (donidalorsen) gives CELYSTRA a first‑in‑class, RNA‑targeted prophylaxis for hereditary angioedema (HAE) in patients ≥12 years, with Q4W/Q8W...